Login / Signup

The biological significance of tumor grade, age, enhancement and extent of resection in IDH mutant gliomas: how should they inform treatment decision in the era of IDH inhibitors? Invited review.

Martin J van den BentPim J FrenchDaniel J BratJoerg-Christian TonnMehdi TouatBenjamin M EllingsonRobert J YoungJohan PalludAndreas von DeimlingFelix SahmDominique Figarella BrangerRaymond Y HuangMichael WellerIngo K MellinghoffTim F CloughseyJason T HuseKenneth D AldapeGuido ReifenbergerGilbert YoussefPhilipp KarschniaHoutan NoushmehrKatherine B PetersFrancois DucrayMatthias PreusserPatrick Yung Wen
Published in: Neuro-oncology (2024)
The 2016 and 2021 World Health Organization (WHO) 2021 Classification of Central Nervous System (CNS) tumors have resulted in a major improvement of the classification of IDH-mutant gliomas. With more effective treatments many patients experience prolonged survival . However, treatment guidelines are often still based on information from historical series comprising both patients with IDHwt and IDH mutant tumors. They provide recommendations for radiotherapy and chemotherapy for so-called high-risk patients, usually based on residual tumor after surgery and age over 40. More up-to-date studies give a better insight into clinical, radiological and molecular factors associated with outcome of patients with IDH-mutant glioma. These insights should be used today for risk stratification and for treatment decisions. In many patients with an IDH-mutant grade 2 and grade 3 glioma, if carefully monitored postponing radiotherapy and chemotherapy is safe, and will not jeopardize overall outcome of patients. With the INDIGO trial showing patient benefit from the IDH inhibitor vorasidenib, there is a sizable population in which it seems reasonable to try this class of agents before recommending radio-chemotherapy with its delayed adverse event profile affecting quality of survival. Ongoing trials should help to further identify the patients that are benefiting from this treatment.
Keyphrases